Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biocartis

Explore full profile

Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments

Mechelen, BelgiumFounded 2007Biotech & Life Sciences
Valuation $170M Market cap · 2024
Revenue $52M Latest reported FY

About Biocartis

Biocartis is a pioneering molecular diagnostics company dedicated to transforming molecular testing through its unique IdyllaTM platform. The company provides advanced diagnostic solutions designed to improve clinical practice for patients, clinicians, payers, and the broader healthcare industry. Biocartis operates in the molecular diagnostics market, focusing on oncology and infectious diseases. Its primary clients include hospitals, laboratories, and healthcare providers who require rapid and accurate diagnostic results. The business model revolves around the sale of diagnostic instruments and consumables, generating revenue through the continuous use of its proprietary platform and assays. Biocartis makes money by selling its IdyllaTM platform and associated diagnostic tests, which offer quick and reliable results, thereby enhancing patient care and operational efficiency in clinical settings.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2007
Headquarters
Mechelen, Belgium
Listing
IPO 2015
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen

Series A5 investors entered at this stage

  • Aescap
  • Advent Venture Partners
  • Johnson & Johnson Development Corporation
  • KBC
  • Debiopharm Group

Series B and later6 investors entered at this stage

  • Wellcome Trust
  • PMV
  • Korys
  • RMM
  • Philips
  • Hitachi Chemical Diagnostics

Talent

Book a demo to see the people
Employees mapped 311 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
19 countries with
team presence
🇧🇪 Belgium70.5%
🇺🇸 United States13.3%
🇩🇪 Germany2.9%
🇮🇹 Italy2.5%
🇫🇷 France2.5%
Top 5 of 19 shown
Web traffic by country
9.1K monthly visits
across markets
🇹🇼 Taiwan28.6%
🇧🇪 Belgium23.1%
🇺🇸 United States22%
🇪🇸 Spain17.6%
🇵🇱 Poland4.4%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biocartis on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biocartis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles